Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome–positive patients with acute lymphoblastic.

Slides:



Advertisements
Similar presentations
Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD by Attilio.
Advertisements

Long-term outcome of patients in the LNH-98
Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry by Gunnar Juliusson, Petar Antunovic,
UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia.
Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.
Hairy Cell Leukemia Variant Has Similar Survival to Classical Disease Despite Poorer Responses to Initial Therapy: A 30-Year Experience from Memorial Sloan.
How I treat HHV8/KSHV-related diseases in posttransplant patients by Giovanni Riva, Mario Luppi, Patrizia Barozzi, Fabio Forghieri, and Leonardo Potenza.
Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia by Robin Foà, Antonella Vitale,
High Cure Rates of the Short-Term GITIL Chemotherapy Programme for Adult Patients with Burkitt Lymphoma by Jacopo Mariotti, Anna Guidetti, Michele Magni,
Interferon-alfa for chronic myeloid leukemia
Martinelli G et al. Proc ASH 2015;Abstract 679.
CALR mutations in patients with essential thrombocythemia diagnosed in childhood and adolescence by Fiorina Giona, Luciana Teofili, Sara Capodimonti, Marica.
by James O. Armitage, and Dan L. Longo
Dasatinib induces complete remission in a patient with primary cerebral involvement of B-cell chronic lymphocytic leukemia failing chemotherapy by Georg.
Retroviral and Chemical Mutagenesis Identifies Pax5 as a Tumor Suppressor in B-Progenitor Acute Lymphoblastic Leukemia by Jinjun Dang, Charles G Mullighan,
Outcomes in Patients with Chronic Myeloid Leukemia (CML) Who Are Treated with Imatinib As Front Line Therapy by Kendra L. Sweet, Najla H Al Ali, Jeffrey.
Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants by.
Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993.
How I treat elderly patients with myeloma
Allogeneic Hematopoietic Stem Cell Transplantation for Philadelphia-Positive Acute Lymphoblastic Leukemia in Children and Adolescents: A Retrospective.
Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia by Alida Dominietto, Sarah Pozzi, Maurizio Miglino, Flavio Albarracin,
Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma.
MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia by Agostino Tafuri, Chiara.
Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib by Jorge.
Autologous Transplantation Therapy for Chronic Myelogenous Leukemia
Comparison of the efficacy of rabbit and horse antithymocyte globulin for the treatment of severe aplastic anemia in children by Ayami Yoshimi, Charlotte.
What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):
Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia.
The Outcome of Sibling and Unrelated Donor Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia in First Remission Who Were.
Protease inhibitors potentiate chemotherapy-induced neutropenia
In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first.
Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute.
New approach for bone marrow transplantation in patients with class 3 thalassemia aged younger than 17 years by Pietro Sodani, David Gaziev, Paola Polchi,
by Jayesh Mehta Blood Volume 112(2): July 15, 2008
First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic.
by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle
Imatinib for refractory chronic graft-versus-host disease with fibrotic features by Attilio Olivieri, Franco Locatelli, Marco Zecca, Adele Sanna, Michele.
Accurate quantification of minimal residual disease at day 15, by real-time quantitative polymerase chain reaction identifies also patients with B-precursor.
Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation by Enrico Tiacci, Gianluca Schiavoni, Francesco Forconi,
Infants with acute lymphoblastic leukemia and a germline MLL gene are highly curable with use of chemotherapy alone: results from the Japan Infant Leukemia.
CXCR4 expression is associated with survival in familial chronic lymphocytic leukemia, but CD38 expression is not by Naoko Ishibe, Maher Albitar, Iman.
Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone by Patrizia Tosi, Elena.
Imatinib (IM) Plus Thalidomide (Thali), A Effective Combination For The Treatment Of Chronic Myeloid Leukemia (CML) Philadelphia ChromosomePositive (Ph.
Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma by Hannes Kaufmann, Markus Raderer, Stefan Wöhrer,
Final Report Of Single-Center Study Of Chemotherapy Plus Dasatinib For The Initial Treatment Of Patients With Philadelphia-Chromosome Positive Acute Lymphoblastic.
Human acute stem cell leukemia with multilineage differentiation potential via cascade activation of growth factor receptors by Ugo Testa, Giovanni F.
Patient-Reported Outcomes from a Global Phase 3 Randomized Controlled Trial of Inotuzumab Ozogamicin Versus Standard of Care Chemotherapy for Relapsed/Refractory.
by Martin S. Tallman, Donna Neuberg, John M. Bennett, Christopher J
by John Anastasi, Rizwan Moinuddin, and Christopher Daugherty
Jacob M. Rowe  Biology of Blood and Marrow Transplantation 
Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years  Cynthia Huisman,
The 10-year cumulative incidence of CRC death or death due to other causes in patients treated with adjuvant chemotherapy after surgery for stages II–III.
Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia by Philip.
Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia.
Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia by Francesco.
Kaplan-Maier survival curves of 10-year DFS (A and B) and OS (C and D) according to PS 0 and PS≥1 in patients treated with adjuvant chemotherapy after.
Transplantation Conditioning Regimens and Outcomes after Allogeneic Hematopoietic Cell Transplantation in Children and Adolescents with Acute Lymphoblastic.
Allogeneic Bone Marrow Transplantation in First Remission for Children with Ultra-high- risk Features of Acute Lymphoblastic Leukemia: A Children’s Oncology.
Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naive Patients Aged ≥65 Years with Acute Myeloid Leukemia by Andrew Wei, Stephen.
Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.
Peripheral T-cell lymphomas unspecified presenting in the skin: analysis of prognostic factors in a group of 82 patients by Marcel W. Bekkenk, Maarten.
A, Overall survival of patients treated with CAR T cells (black line; n = 15). A, Overall survival of patients treated with CAR T cells (black line; n.
Mary Eapen  Biology of Blood and Marrow Transplantation 
Allogeneic Stem Cell Transplantation versus Tyrosine Kinase Inhibitors Combined with Chemotherapy in Patients with Philadelphia Chromosome–Positive Acute.
Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia by Robin Foà, Antonella Vitale,
Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG.
by Jan J. Cornelissen, and Didier Blaise
Health-Related Quality of Life (HRQoL) of Blinatumomab Versus Standard of Care (SOC) Chemotherapy in Patients with Relaspsed or Refractory Philadelphia.
Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and.
Cold agglutinin disease
Presentation transcript:

Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome–positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol by Marco Vignetti, Paola Fazi, Giuseppe Cimino, Giovanni Martinelli, Francesco Di Raimondo, Felicetto Ferrara, Giovanna Meloni, Achille Ambrosetti, Giovanni Quarta, Livio Pagano, Giovanna Rege-Cambrin, Loredana Elia, Raffaello Bertieri, Luciana Annino, Robin Foà, Michele Baccarani, and Franco Mandelli Blood Volume 109(9):3676-3678 May 1, 2007 ©2007 by American Society of Hematology

Median probability of survival. Median probability of survival. Overall survival (A) and disease-free survival (B) probability in elderly (> 60 years) patients with Ph+ ALL, treated with imatinib plus steroids. Marco Vignetti et al. Blood 2007;109:3676-3678 ©2007 by American Society of Hematology

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.